Ranbaxy Mohali Plant Worries Continue
  • Elizabeth George
  • Sep 17 2013

September 17: Ranbaxy has come under the USFDA spotlight yet again for all the wrong reasons. After a record $500 million settlement, the worries for the Mohali plant now take centre stage. Ranbaxy has just issued a statement saying steps will be taken to resolve FDA concerns. Bloomberg TV India tells you that a third-party inspection of the Mohali plant will be likely and what the company needs to do to salvage the situation.